Moffitt | Strategic Alliance Partners

Latest from Moffitt

Pursuing PARP Beyond HRD+ Ovarian Cancer

April 09, 2021

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

HEPZATO Demonstrates Promising Preliminary Activity in Metastatic Ocular Melanoma

March 31, 2021

HEPZATO KIT has demonstrated statistically significant benefit compared to best alternative care in patients with liver-dominant metastatic ocular melanoma, according to preliminary results from the phase 3 FOCUS trial.